Leukemia & Lymphoma

Papers
(The H4-Index of Leukemia & Lymphoma is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study50
Impact of SF3B1 mutation in myelofibrosis45
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents31
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma29
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans27
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy26
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis23
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini23
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia22
Organ toxicities associated with chimeric antigen receptor T-cell therapy22
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation20
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax18
Hypereosinophilia after CAR T-cell therapy18
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)18
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity17
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma17
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review16
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports16
0.15941286087036